The board of directors of the RemeGen Co., Ltd. announced that the Company has completed the Phase III confirmatory study for telitacicept (RC18) to treat patients with systemic lupus erythematosus (SLE) in China and obtained the preliminary data readout. The study included 335 patients who were randomized to receive telitacicept (160mg) or placebo subcutaneously once a week in combination with standard therapy for 52 weeks. Preliminary result from full analysis set (FAS) showed there was a significantly higher response rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) in patients received telitacicept than in patients received placebo (82.6% vs.

38.1%, p<0.001) at week 52. Results of all the sensitivity analyses showed a significantly higher response rate of SRI-4 in patients received telitacicept than in patients received placebo (p<0.001). Thus, this study meets its primary endpoint SRI-4 and detailed results will be presented in an upcoming international conference.

The result is consistent with what have obtained earlier phases studies have conducted in China.